Following on from information provided to NICE by the company in December 2021 the appraisal of Epicutaneous immunotherapy for treating peanut allergy in children was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1255 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 November 2022 | Discontinued. Following on from information provided to NICE by the company in December 2021 the appraisal of Epicutaneous immunotherapy for treating peanut allergy in children was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 March 2022 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Epicutaneous immunotherapy for treating peanut allergy in children. For information, the company has advised that they have withdrawn their Marketing Authorisation Application from the European Medicines Agency (EMA) for this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 26 October 2021 | As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Epicutaneous immunotherapy for treating peanut allergy in children. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-March 2022 when we will write to consultees and commentators about how they can get involved. |
| 24 November 2020 - 21 December 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual